Results 141 to 150 of about 17,658 (223)

Efficacy and safety of nab-paclitaxel in advanced or recurrent small cell lung cancer: a single-arm meta-analysis. [PDF]

Front Pharmacol
Liu JC, Yu HJ, Chen Z, Deng Q.
europepmc   +1 more source

Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab-Paclitaxel as First-Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer. [PDF]

Cancer Rep (Hoboken)
Ikezawa K, Imai T, Takada R, Yamai T, Fukutake N, Urabe M, Kai Y, Mukai K, Nakabori T, Ohkawa K.   +9 more
europepmc   +1 more source

Idiopathic Bell's Palsy in a Patient With Metastatic Lung Adenocarcinoma Receiving Nab-Paclitaxel and Pregabalin: A Rare Clinical Observation. [PDF]

Case Rep Oncol Med
Bamane V, Thakre S, Dhanawat A, Chepuri G, Joshi A, Gota V, Krishnamurthy MN.   +6 more
europepmc   +1 more source

Analysis of outcomes of nab-paclitaxel compared to other taxanes in early breast cancer: A study revealing the critical role of calendar-time bias in real-world drug comparisons. [PDF]

Breast
Xiao J, Huang M, Yan C, Wang Z, Wang T.
europepmc   +1 more source

L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial. [PDF]

Nat Cancer
Gong J, Muranaka H, Choi SY, Tighiouart M, Bhute S, Aja ER, Jacobs JP, Stotland A, Van Eyk J, Elmadbouh OHM, Edderkaoui M, Tanaka S, Furuya H, Osipov A, Lorber J, Billet S, Morris A, Ten Hoeve-Scott J, Graeber T, Pandol SJ, Hendifar A, Bhowmick NA.   +21 more
europepmc   +1 more source

Corrigendum to "Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer" [Redox Biol. 88 (2025) 103895]. [PDF]

Redox Biol
Jameson GS, Danielle LeGrand S, Gordon MS, Roe DJ, Wertheim BC, Olszewski K, Rabinowitz J, Evans R, Downes M, Truitt M, Korn R, Han H, Miller RM, Barrett MT, Propper D, Von Hoff DD, Borazanci E.   +16 more
europepmc   +1 more source

Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. [PDF]

Nat Commun
Raufi AG, D'Souza EK, May MS, Sedycias S, Pellicciotta I, Pan S, Wang S, Palermo C, Sastra S, Sender N, Ross I, Li L, Luthria K, Shah P, Tagore S, Walsh ZH, Turk A, Sema B, Iuga A, Dajiang S, Kluger MD, Schrope BA, Brown D, Fojo T, Schvartzman JM, Pumpalova Y, Moy RH, Bates S, Wu L, Hibshoosh H, Tan AC, Schwartz GK, Chabot JA, Olive KP, Izar B, Manji GA.   +35 more
europepmc   +1 more source

Efficacy of nab-paclitaxel combined with immune checkpoint inhibitors in solid tumors: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Transl Cancer Res
Li X, Song Y, Li J.
europepmc   +1 more source

Optimized chemotherapy sequence for metastatic pancreatic ductal adenocarcinoma patients: FOLFIRINOX followed by Gemcitabine plus nab-paclitaxel. [PDF]

BMC Cancer
Del Campo-Pedrosa R, Martín-Carnicero A, González-Marcos A, Martínez A.   +3 more
europepmc   +1 more source

Treatment of Kaposi's Sarcoma (KS) with nab-paclitaxel

Annals of Oncology, 2016
S. Fortino, M. Santoro, E. Iuliano, M. Luci, A. Perricelli, A. Pomillo   +5 more
openaire   +1 more source